New treatment options for managing chemotherapy-induced neutropenia

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL., 2002, Pages

  Valley, Amy Wells ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Antineoplastic agents; Colony stimulating factors; Hematopoietic agents; Neutropenia; Pegfilgrastim; Toxicity

Indexed keywords

BLEOMYCIN; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMINE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLONY FORMATION; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG INDUCED DISEASE; FEBRILE NEUTROPENIA; HEALTH CARE COST; HOSPITALIZATION; HUMAN; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; LUNG TUMOR; NONHODGKIN LYMPHOMA; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONY-STIMULATING FACTORS; FILGRASTIM; HUMANS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; NEUTROPENIA; SEVERITY OF ILLNESS INDEX;

EID: 0036685406     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_4.s11     Document Type: Conference Paper

References (18)

1. American Society of Clinical Oncology 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American society of clinical oncology growth factors expert panel
2. Hematopoietic growth factors for patients with cancer
3. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma
4. A single scale for comparing dose intensity of all chemotherapy regimens in breast cancer: Summation dose intensity
5. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
6. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
7. Modeling the cost-effectiveness of granulocyte-stimulating factor use in early stage breast cancer
8. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer; findings from the national surgical adjuvant breast and bowel project B-22
9. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from the national surgical breast and bowel project B-25
10. A cost analysis of hematopoietic colony-stimulating factors
11. The economics of febrile neutropenia: Implications for the use of colony-stimulating factors
12. Filgrastim (r-metHUG-CSF) in the 21st century: SD/01
13. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs
14. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy
15. Blinded, randomized, multicenter: Study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
16. A randomized, double-blind, Phase 3 study evaluating fixed-dose, once-per-cycle pegylated filgrastim (SD/01) vs daily filgrastim to support chemotherapy for breast cancer